<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04572516</url>
  </required_header>
  <id_info>
    <org_study_id>MS 3-11-2019</org_study_id>
    <nct_id>NCT04572516</nct_id>
  </id_info>
  <brief_title>Botulium Toxin Type A In Non Infectious Chronic Rhinosinusitis</brief_title>
  <official_title>Topical Application Versus Intra Turbinate Injection of Botulium Toxin Type A In The Treatment of Non Infectious Chronic Rhinosinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present work aims to assess the effectiveness and safety of topical application of BTX -&#xD;
      A compared with its intra turbinate injection in controlling the symptoms in non infectious&#xD;
      chronic rhinosinusitis patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective comparative study will be carried out on 30 participant of both sex at&#xD;
      Otorhinolaryngology Department, Benha University Hospital, it will include patients suffering&#xD;
      from non infectious chronic rhinosinustitis symptoms in the form of nasal blockage,&#xD;
      rhinorrhea, itching and/or sneezing.&#xD;
&#xD;
      The patients will be divided randomly into two groups:&#xD;
&#xD;
        -  Group A (topical group) : 15 patients&#xD;
&#xD;
        -  Group B (injected group) : 15 patients&#xD;
&#xD;
      All patients will be subjected to:&#xD;
&#xD;
        1. Full clinical evaluation:&#xD;
&#xD;
           A) Full history taking B) Clinical examination by&#xD;
&#xD;
             -  anterior rhinoscopy to evaluate the nasal cavity to exclude purulent discharge ,&#xD;
                nasal polyps or anterior septal deviation.&#xD;
&#xD;
             -  nasal endoscopy to exclude nasal infection signs ,nasal polyps ,the posterior&#xD;
                septal deviation or adenoid .&#xD;
&#xD;
           C) Investigations:CT nose and paranasal sinuses coronal cuts to exclude fungal&#xD;
           sinusitis, nasal polyps or other structural abnormalities e.g; posterior septal&#xD;
           deviation, conchae bullosa or any other nasal pathology .&#xD;
&#xD;
        2. Intervention :&#xD;
&#xD;
             -  BTX -A available in the Egyptian market in the form of powder vial (Allergan)&#xD;
                containing 100 Units, will be dissolved in 10 cc saline to obtain clear colorless&#xD;
                solution in which each 1cc contain 10 Units.&#xD;
&#xD;
             -  In group A (topical group) ,topical application in the form of merocel soaked with&#xD;
                20 units of BTX_A (2ml) will be placed at each side of the nasal cavity for 30&#xD;
                minutes.&#xD;
&#xD;
             -  In group B (injected group), 20 units of BTX_A (2ml) will be injected submucosally&#xD;
                in each inferior turbinate using insulin syringe needle after local anesthesia&#xD;
                using 10% xylocaine spray .&#xD;
&#xD;
        3. Follow Up Follow up visits will be at 1,2,4,6,8 weeks, patients will be assessed and&#xD;
           questionnaired about severity of the symptoms and possible adverse effects including&#xD;
           epistaxis and nasal dryness .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Actual">July 15, 2021</completion_date>
  <primary_completion_date type="Actual">June 15, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the rhinitis symptom severity</measure>
    <time_frame>2 months</time_frame>
    <description>the rhinitis symptom severity questionnaire, this is questionnaire consists of 4 items (nasal obstruction, rhinorrhea , sneezing and or nasal itching) . each symptom given score from 0 to 3 ( 0 = none, 1 = mild, 2 = moderate and 3 = severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>possible adverse effects</measure>
    <time_frame>2 months</time_frame>
    <description>epistaxis and nasal dryness (yes/no)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Chronic Rhinosinusitis (Diagnosis)</condition>
  <arm_group>
    <arm_group_label>Topical group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application in the form of merocel soaked with 20 units of BTX_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injection group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 units of BTX_A (2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BTX A Topical</intervention_name>
    <description>In group A (topical group) ,topical application in the form of merocel soaked with 20 units of BTX_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.</description>
    <arm_group_label>Topical group</arm_group_label>
    <other_name>Topical</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BTX A Injection</intervention_name>
    <description>In group B (injected group), 20 units of BTX_A(2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .</description>
    <arm_group_label>Injection group</arm_group_label>
    <other_name>Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with persistent symptoms of chronic non infectious rhinosinusitis not&#xD;
             responding to previous lines of treatment including antihistaminics ,nasal&#xD;
             decongestant, and or nasal steroid spray will be included in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with major structural deformities(septal deviation , adenoid hypertrophy,&#xD;
             nasal valve pathology or nasal polyps).&#xD;
&#xD;
          -  Having systemic illness such as DM, HTN, Malignancy or Tuberculosis.&#xD;
&#xD;
          -  History of nasal surgery such as turbinate reduction surgery orseptoplasty.&#xD;
&#xD;
          -  Acute rhinosinusitis findings; e.g purulent or mucopurulent nasal discharge&#xD;
&#xD;
          -  Radiological finding of nasal tumors or fungal sinusitis.&#xD;
&#xD;
          -  Any accompanying disease such as glaucoma or prostate hypertrophy or myasthenia that&#xD;
             might be aggravated by anticholinergic therapy .&#xD;
&#xD;
          -  use of systemic or local corticosteroid less than 1 month prior the study.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  History of allergy to botox or local anesthetic agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdelrahman A Abdelalim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benha Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed A Elsayed, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Benha Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Naslshah G Kazeem, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Benha Faculty of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aya L Hassan, Resident</last_name>
    <role>Study Chair</role>
    <affiliation>Benha University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Benha University Hospital, Faculty of Medicine</name>
      <address>
        <city>Banhā</city>
        <state>Qalubia</state>
        <zip>13512</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Zhang EZ, Tan S, Loh I. Botolinum toxin in rhinitis: Literature review and posterior nasal injection in allergic rhinitis. Laryngoscope. 2017 Nov;127(11):2447-2454. doi: 10.1002/lary.26616. Epub 2017 Jul 6. Review.</citation>
    <PMID>28681969</PMID>
  </reference>
  <reference>
    <citation>Ozcan C, Vayisoglu Y, Doğu O, Görür K. The effect of intranasal injection of botulinum toxin A on the symptoms of vasomotor rhinitis. Am J Otolaryngol. 2006 Sep-Oct;27(5):314-8.</citation>
    <PMID>16935174</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 26, 2020</study_first_submitted>
  <study_first_submitted_qc>September 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Abdelrahman Ahmed Abdelalim</investigator_full_name>
    <investigator_title>MD Lecturer</investigator_title>
  </responsible_party>
  <keyword>Chronic rhinosinustitis</keyword>
  <keyword>Botulium Toxin A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

